- Home
- AYI vs LEGN Comparison
AYI vs LEGN Comparison
Compare AYI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYI
- LEGN
- Stock Information
- Founded
- AYI 2001
- LEGN 2014
- Country
- AYI United States
- LEGN United States
- Employees
- AYI N/A
- LEGN N/A
- Industry
- AYI Building Products
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AYI Consumer Discretionary
- LEGN Health Care
- Exchange
- AYI Nasdaq
- LEGN Nasdaq
- Market Cap
- AYI 10.2B
- LEGN 6.7B
- IPO Year
- AYI N/A
- LEGN 2020
- Fundamental
- Price
- AYI $339.95
- LEGN $34.41
- Analyst Decision
- AYI Buy
- LEGN Strong Buy
- Analyst Count
- AYI 5
- LEGN 12
- Target Price
- AYI $352.60
- LEGN $73.36
- AVG Volume (30 Days)
- AYI 221.1K
- LEGN 1.1M
- Earning Date
- AYI 10-01-2025
- LEGN 11-11-2025
- Dividend Yield
- AYI 0.20%
- LEGN N/A
- EPS Growth
- AYI 3.17
- LEGN N/A
- EPS
- AYI 12.69
- LEGN N/A
- Revenue
- AYI $4,168,800,000.00
- LEGN $796,838,000.00
- Revenue This Year
- AYI $14.58
- LEGN $70.75
- Revenue Next Year
- AYI $8.88
- LEGN $52.47
- P/E Ratio
- AYI $26.49
- LEGN N/A
- Revenue Growth
- AYI 9.16
- LEGN 74.75
- 52 Week Low
- AYI $216.81
- LEGN $27.34
- 52 Week High
- AYI $345.30
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- AYI 52.62
- LEGN 44.28
- Support Level
- AYI N/A
- LEGN $32.70
- Resistance Level
- AYI $342.72
- LEGN $34.71
- Average True Range (ATR)
- AYI 7.79
- LEGN 1.20
- MACD
- AYI -12.68
- LEGN 0.01
- Stochastic Oscillator
- AYI 98.22
- LEGN 44.25
About AYI Acuity Brands Inc.
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.